

Dr Rachel Drayton

Cardiff Royal Infirmary

Fourth Joint Conference *of the* British HIV Association *with the* British Association for Sexual Health and HIV
Edinburgh International Conference Centre ♦ 17–20 April 2018



**Prosiect PrEP Cymru
Wales PrEP Project**

The Welsh experience

Dr Rachel Drayton

Consultant in GU medicine and HIV, Cardiff Royal Infirmary

Pecuniary declaration of interests - None



Lead Authors: Adam Jones, Public Health Practitioner - Policy
Zoë Couzens, Principal in Public Health, Health Protection

Contributors: HIV Expert Group	
Date: 30 th November 2016	Version: 1

Publication/ Distribution:

- NHS Wales (Intranet)

Review Date: To be subject to regular updates, twelve months from

publication of the review, or on emergence of significant new evidence.

Purpose and Summary of Document:

This document provides an overview of the current evidence related to the provision of Pre-Exposure Prophylaxis (PrEP) for HIV prevention, featuring

an extensive review of the available evidence for specific aspects of the subject, analysis of clinical trials, the policy, regulatory and legislative context, and global perspectives.

Work Plan reference:

- Strategic Priorities 5.B.6

• *STRASSER, FRIEDRICH & U. V.*

Nov 2016
Evidence review



Last Updated: 15th March 2017

Mar 2017
Management
guidelines



Reference No. 1625 Publication date: 12/11/2015

ertitacin/erteclovir disodium (Teva) 200 mg/245 mg film-coated tablet

Company: (R&D categories)	Gilad Sciences Ltd Infectious	Submission Type: Status	Full Submission Not recommended
-------------------------------------	----------------------------------	-----------------------------------	------------------------------------

WBG meeting date:	08/03/2017	Advised by:	08/17
WAMSG meeting date:	26/06/2017	Ratification by Welsh Government:	11/06/2017

Current Progress



Submission status	MAG rating	AMSG rating	Reflexion by Wahlg (percentage)
----------------------	---------------	----------------	------------------------------------

AWMSG advice

Entecavir/tenofovir disoproxil fumarate (Truvada) is not recommended for use within NHS Wales in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. The case for cost-effectiveness has not been proven.

Subsequent to AHS/MSG recruitment, this medicine has been made available in Wales, Toronto for use as pre-exposure prophylaxis is being provided through NHS Wales from 17 July 2017 for up to three years. During this time, all those who are eligible will receive Toronto and data will be collected as adherence, acceptability and HIV/SST status. This information will help assess its effectiveness at preventing HIV and address some of concerns of AHS/MSG in relation to cost effectiveness. Data collected will help inform any future decisions about the future provision through NHS Wales.

Apr 2017 All
Wales
Medicines
Strategy Group



A Project Scope and Study Protocol for the Implementation of Pre-Exposure Prophylaxis (PrEP) in Wales

Adam Jones, Public Health Practitioner – Policy, Public Health Wales
Zoë Couzens, Principal Health Protection Specialist, Public Health Wales

Dr. Giri Shankar, Professional Lead Consultant in Health Protection, Public Health Wales & Chair of Independent HIV Expert Group

July 2017 Version 2

June 2017 –
PrEPared
Protocol


Apr 2017 –
Cabinet
Secretary
announcement

Health Secretary Vaughan Gething announces all-Wales PrEP trial

The Health Secretary Vaughan Gething has announced an all-Wales study to provide the drug Truvada® to all those who would benefit from the preventative treatment.

The Health Secretary Vaughan Gething has announced an all-Wales study to provide the drug Truvada® to all those who would benefit from the preventative treatment.

Friday 28 April 2017



Pre-Exposure Prophylaxis (PrEP) for HIV - Operational Guide

Last Updated: 6th July 2017


July 2017 –
Operational
guide and PrEP
provision on the
NHS

The detail


- **Eligibility criteria:**
 - **Category 1 - MSM engaging in condomless anal sex in last 3 months**
 - **Category 2 – Partners of PLWH with detectable VL**
 - **Category 3 – Heterosexuals with high risk partners**
- **33 new clinical codes**

The context

- Approx 4200 MSM attending annually:
 - Predicted 500 eligible
- Reimbursement drug and additional testing costs




Proposed clinic pathway




The headline figures


- In first 9 months:
 - 378 eligible and 261 started
 - 98% category 1



Amended clinic pathway



Unexpected challenges




■ Patients with standard monitoring


■ Patients requiring additional renal monitoring

“It’s like running another HIV clinic list as this patient group are so complex to manage”

Impact on other services



Impact on other services



How accurate will the data be?

- **3 out of the top 5 clinician concerns coding related**
 - **Time taken**
 - **Accuracy – of those given PrEP and those not given PrEP**

Are we collecting the right data?

- Large gradient of risk within eligibility category 1

“Men are aware of the eligibility criteria and know what to say”


“Punishing men who are consistently using condoms by denying them PrEP”

PrEP criteria for urgent prioritisation:

- > 5 partners in last month
- > 2 partners in last month AND reported condom usage <50%
- Sex work/chemsex/using drugs/sex toys/cruising/group sex last 3 months
- Known HIV positive partner with detectable VL
- Diagnosed with rectal GC, CT, syphilis or HCV in last 3 months
- < 18 years old

Are we collecting the right data?

- 22% eligible patients declined PrEP



Looking forward

- **Is PrEP provision sustainable in Wales without adequate funding?**
- **What will be the impact on other services provided?**
- **Is the current method of data collection adequate?**
- **Are we sure the eligibility criteria are right for our population?**

Acknowledgements

- All the sexual health clinicians across Wales for working tirelessly to provide PrEP and participate in data collection and completing surveys
- Colleagues in Public Health Wales, for providing operational and management guidelines, and analysing data, especially:
 - Zoe Couzens
 - Adam Jones
 - Laia Fina Homer
 - Amy Phillips